Daan Gene (002030) Stock Overview
Researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
002030 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Daan Gene Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.55 |
| 52 Week High | CN¥8.20 |
| 52 Week Low | CN¥5.17 |
| Beta | 0.40 |
| 1 Month Change | -14.35% |
| 3 Month Change | -7.19% |
| 1 Year Change | -3.65% |
| 3 Year Change | -44.22% |
| 5 Year Change | -73.91% |
| Change since IPO | -58.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002030 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 3.2% | -1.3% | 4.7% |
| 1Y | -3.6% | -20.7% | 35.4% |
Return vs Industry: 002030 exceeded the CN Biotechs industry which returned -20.7% over the past year.
Return vs Market: 002030 underperformed the CN Market which returned 35.4% over the past year.
Price Volatility
| 002030 volatility | |
|---|---|
| 002030 Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.6% |
| 10% least volatile stocks in CN Market | 4.4% |
Stable Share Price: 002030 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002030's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 1,506 | Chen Hong wei | www.daangene.com |
Daan Gene Co., Ltd., together with its subsidiaries, researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables in China. It operates through two segments, Biological Products and Related Business and Financial Business. The company offers reagents for hepatitis virus, sexually transmitted infections, blood screening, digestive pathogens, coronavirus disease (COVID-19), pharmacogenomics, viral transport medium, human papillomavirus, human immunodeficiency virus, respiratory infections, public health, tumor maker, and nucleic acid extraction, as well as polymerase chain reaction, sample preparation, and nucleic extraction systems for molecular diagnosis; COVID-19 rapid test kit and chemiluminescence immunoassay analyzers for immunoassay; liquid based cytology production and automatic sample transfer machines for pathology tests; and auto biochemistry analyzers and chemistry reagents for clinical chemistry.
Daan Gene Co., Ltd. Fundamentals Summary
| 002030 fundamental statistics | |
|---|---|
| Market cap | CN¥7.79b |
| Earnings (TTM) | -CN¥895.46m |
| Revenue (TTM) | CN¥737.96m |
Is 002030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002030 income statement (TTM) | |
|---|---|
| Revenue | CN¥737.96m |
| Cost of Revenue | CN¥655.18m |
| Gross Profit | CN¥82.78m |
| Other Expenses | CN¥978.24m |
| Earnings | -CN¥895.46m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 11.22% |
| Net Profit Margin | -121.34% |
| Debt/Equity Ratio | 1.7% |
How did 002030 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/20 15:17 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Daan Gene Co., Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kubie Zhou | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Weina Jiang | Everbright Securities Co. Ltd. |
| Weina Jiang | Guosen Securities Co., Ltd. |